МЕНОПАУЗАЛЬНАЯ ГОРМОНОТЕРАПИЯ С ДИДРОГЕСТЕРОНОМ: АСПЕКТЫ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ УЛЬТРАНИЗКИХ ДОЗ
https://doi.org/10.21518/2079-701X-2017-2-92-99
Аннотация
В ряде исследований показано, что менопаузальная гормонотерапия (МГТ), состоящая из 1 мг 17ß-эстрадиола и 5 мг дидрогестерона, является эффективной для снижения выраженности климактерических симптомов и повышения мине- ральной плотности костей у женщин в постменопаузе [1, 2] и в то же время имеет благоприятные показатели безопасности для эндометрия и паттерна кровотечений [3, 4]. Тем не менее современные руководства рекомендуют использовать для лечения симптомов менопаузы наименьшие эффективные дозы эстрогенов [5–7]. В связи с этим был разработан новый комбинированный режим МГТ с непрерывным использованием сверхнизких доз гормонов – 0,5 мг 17ß-эстрадиола и 2,5 мг дидрогестерона. Использование ультранизких доз эстрогенов позволяет обеспечить защиту эндометрия более низкими дозами прогестагенов. Подобные низкодозовые комбинации МГТ могут снизить частоту возникновения нежелательных явлений, таких как чувствительность молочных желез, маточные кровотечения, сердечно-сосудистые заболевания, ишемический инсульт и венозные тромбоэмболические осложнения, и в то же время сохранить эффективность в отношении климактерических симптомов [8–12]. Появление в арсенале гинекологов ультранизкодозированной МГТ, вероятно, улучшит приверженность пациентов данному режиму лечения. Кроме того, низкие дозы эстрогенов особенно полезны для женщин старшего возраста (более 59 лет).
Об авторе
А. А. Сметник
Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России
Россия
Россия
к.м.н.,
Москва
Список литературы
1. Stevenson JC, Teter P, Lees B. 17β-Oestradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas, 2001, 38: 197–203.
2. Медицина климактерия. Под ред. В.П. Сметник. М.: Литера, 2006. 846 с.
3. Quereux C, Pornel B, Bergeron C, Ferenczy A. Continuous combined hormone replacement therapy with 1 mg 17β-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas, 2006, 53: 299–305.
4. Bergeron C, Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17β-oestradiol (1 or 2 mg) and dydrogesterone. Maturitas, 2001, 37: 191–199.
5. Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human. Core SmPC for Hormone Replacement Therapy. Updated: 2004.
6. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010, 17:242–255.
7. Baber RJ, Panay N, Fenton A. The IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy, Climacteric, 2016, 19(2):109-150.
8. Ettinger B. Rationale for the use of lower estrogen doses for postmenopausal hormone therapy. Maturitas, 2007, 57: 81–84.
9. Van de Weijer PHM, Mattsson L-A, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas, 2007, 56: 231–248.
10. Johansen OE, Qvigstad E. Rationale for lowdose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Adv Ther, 2008, 25: 525–551.
11. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric, 2007, 10: 120–131.
12. Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas, 2008, 59: 2–6.
13. Mueck AO, Seeger H, Bühling KJ. Use of dydrogesterone in hormone replacement therapy. Maturitas, 2009, 65(1): 51-60.
14. Stevenson JC, Durand G, Kahler E et al. Oral ultra-low dose continuous com-bined hormone replacement therapy with 0.5 mg 17betaoestradiol and 2.5 mgdydrogesterone for the treatment of vasomotor symptoms: results from adouble-blind, controlled study. Maturitas, 2010, 67: 227–32.
15. Cieraad D, Conradt C, Jesinger D, et al. Clinical study comparing the effects ofsequential hormone replacement therapy with oestradiol/dydrogesterone andconjugated equine oestrogen/norgestrel on lipids and symptoms. Archives of Gynecology and Obstetrics, 2006, 274: 74–80.
16. Репина М.А. Проблемы менопаузального перехода: низкодозированная заместительная гормональная терапия микронизированным эстрадиолом в сочетании с дидрогестероном. Фарматека, 2008; 14: 39-44.
17. Kok AL, Burger CW, van de Weijer PH, et al. Micturition complaintsin postmenopausal women treated with continuously combined hormonereplacement therapy: a prospective study. Maturitas, 1999, 31: 143–9.
18. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-doseDHEA therapy on climacteric symptoms and female sexuality. Climacteric, 2011, 14: 661–8.
19. Sturdee DW, Panay N. Recommendations for the management of post-menopausal vaginal atrophy. Climacteric, 2010, 13: 509–22.
20. Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebocontrolled study on the influence of a hormone replacement therapyon skin aging in postmenopausal women. Climacteric, 2007, 10: 320–34.
21. Тихомиров А.Л., Олейник Ч.Г. Проблемы климактерия и заместительная гормональная терапия у женщин в постменопаузе с использованием препарата «Фемостон (1/5)». РМЖ. 2003. 14. 808.
22. Utian, W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes, 2005, 3: 47–56.
23. Rödström K, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause, 2002, 9: 156–161.
24. Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol, 2008, 51: 539–548.
25. AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract, 2006, 12: 315–337.
26. Manson JE, Hsia J, Johnson KC et al, Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med, 2003, 349: 523–534.
27. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol, 2000, 95: 726–731.
28. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause, 2000, 7: 310–317.
29. Pauline MM. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause, 2008, 15(5): 848-856.
30. Jackson RD, Wactawski-Wende J, LaCroix AZ et al. Effects of conjugated equineestrogen on risk of fractures and BMD in postmenopausal women with hys-terectomy: results from the women’s health initiative randomized trial. Journalof Bone and Mineral Research, 2006, 21: 817–28.
31. Christenson ES, Jiang X, Kagan R, et al. Osteoporosis management in post-menopausal women. Minerva Ginecologica, 2012, 64: 181–94.
32. Tobias JH, Clarke S, Mitchell K, et al. Analysis of the contribution of dydro-gesterone to bone turnover changes in postmenopausal women commencinghormone replacement therapy. The Journal of Clinical Endocrinology & Metabolism, 2001, 86: 1194–8.
33. Lippuner K, Haenggi W, Birkhaeuser MH, et al. Prevention of postmenopausalbone loss using tibolone or conventional peroral or transdermal hormonereplacement therapy with 17betaestradiol and dydrogesterone. Journal of Bone and Mineral Research, 1997, 12: 806–12.
34. Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int, 2001, 12(4): 251-8.
35. Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas, 2013, 76: 10-21.
36. Ettinger B, Genant HK, Steiger P et al. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. American Journal of Obstetrics and Gynecology, 1992, 166(2): 479-488.
37. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 2002, 288: 321–333.
38. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 2004, 291: 1701–1712.
39. American Heart Association Science Advisory and Coordinating Committee. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation, 2007, 115: 1481–1501.
40. Stevenson JC, Rioux JE, Komer L et al. 1 and 2 mg 17beta-estradiol combinedwith sequential dydrogesterone have similar effects on the serum lipid profileof postmenopausal women. Climacteric, 2005, 8: 352–9.
41. Kwok S, Charlton-Menys V, Pemberton P, et al. Effects of dydrogesterone andnorethisterone, in combination with oestradiol, on lipoproteins and inflamma-tory markers in postmenopausal women. Maturitas, 2006, 53: 439–46.
42. Pornel B, Chevallier O, Netelenbos JC. Oral 17betaestradiol (1 mg) contin-uously combined with dydrogesterone improves the serum lipid profile ofpostmenopausal women. Menopause, 2002, 9: 171–8.
43. Gelfand M, Fugere P, Bissonnette F. Cardiovascular risk factors during sequen-tially combined 17 beta oestradiol and dydrogesterone (Femoston), resultsfrom a one-year study in postmenopausal women. Maturitas, 1997, 26: 125–32.
44. Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and highdose oestradiol and dydrogesterone therapy on insulin and lipoproteinmetabolism in healthy postmenopausal women. Clinical Endocrinology (Oxford), 2004, 60: 541–9.
45. Manassiev NA, Godsland IF, Crook D, et al. Effect of postmenopausal oestradioland dydrogesterone therapy on lipoproteins and insulin sensitivity, secretionand elimination in hysterectomised women. Maturitas, 2002, 42: 233–42.
46. М.А. Геворкян, И.Б. Манухин, В.В. Казенашев. Опыт применения гормонотерапии при климактерических расстройствах. Фарматека. 2006; №2(117):5-7.
47. Kaya C, Cengiz SD, Cengiz B, et al. Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthypostmenopausal women: a 1-year, randomized, prospective study. Gyne colog-ical Endocrinology, 2007, 23(Suppl. 1): 62–7.
48. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estra-diol/dydrogesterone or other HRT preparations. Climacteric, 2009, 12: 445–53.
49. Simoncini T, Caruso A, Giretti MS et al, Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril, 2006, 86: 1235–1242.
50. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism inusers of hormone replacement therapy. Lancet, 1996, 348: 977–80.
51. Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and riskof venous thrombosis. The Journal of the American Medical Association, 2004, 292: 1573–80.
52. Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the riskof venous thromboembolism: a population-based study. Journal of Thrombosisand Haemostasis 2010, 8: 979–86.
53. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venousthromboembolism among postmenopausal women: impact of the route ofestrogen administration and progestogens: the ESTHER study. Circulation, 2007, 115: 840–5.
54. Mijatovic V, Kenemans P, Netelenbos C et al, Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril, 1998, 69: 876–882.
55. Chiantera V, Sarti CD, Fornaro F et al, Longterm effects of oral and transdermal hormone
56. replacement therapy on plasma homocysteine levels. Menopause, 2003, 10: 286–291.
57. Smolders RG, de Meer K, Kenemans P, Teerlink T, Jakobs C, van der Mooren MJ. Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women. Eur J Obstet Gynecol Reprod Biol, 2004, 117: 55–59.
58. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacementtherapy on cardiovascular events in recently postmenopausal women: ran-domised trial. British Medical Journal, 2012, 345: e6409.
59. Santen RJ, Allred DC, Ardoin SP et al. Postmenopausal hormone therapy: anEndocrine Society scientific statement. The Journal of Clinical Endocrinology & Metabolism, 2010, 95: 1–66.
60. Hanggi W, Lippuner K, Jaeger P, et al. Differential impact of conventional oral ortransdermal hormone replacement therapy or tibolone on body compositionin postmenopausal women. Clinical Endocrinology (Oxford), 1998, 48: 691–9.
61. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of post-menopausal hormone therapy: the Heart and Estrogen/progestin Replace mentStudy. A randomized, double-blind, placebo-controlled trial. Annals of InternalMedicine, 2003, 138: 1–9.
62. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect ofhormone-replacement therapy on components of the metabolic syndrome inpostmenopausal women. Diabetes, Obesity and Metabolism, 2006, 8: 538–54.
63. Sztefko K, Rogatko I, Milewicz T, et al. Effect of hormone therapy on theenteroinsular axis. Menopause, 2005, 12: 630–8.
64. Sturdee DW, Pines A, Archer DF, et al. Updated IMS recommendations on post-menopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2011, 14: 302–20.
65. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestinon breast cancer and mammography in healthy postmenopausal women: theWomen’s Health Initiative Randomized Trial. The Journal of the American Medical Association, 2003, 289: 3243–53.
66. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy andbreast cancer risk in the Women’s Health Initiative randomized trial of estrogenplus progestin. Maturitas, 2006, 55: 103–15.
67. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogenin postmenopausal women with hysterectomy: the Women’s Health Initiativerandomized controlled trial. The Journal of the American Medical Association, 2004, 291: 1701–12.
68. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogenand breast cancer incidence and mortality in postmenopausal women with hys-terectomy: extended followup of the Women’s Health Initiative randomisedplacebo-controlled trial. The Lancet Oncology, 2012, 13: 476–86.
69. Krämer E, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells. Menopause, 2005, 12: 468–474.
70. Seeger H, Rakov V, Mueck AO. Dose dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Horm Metab Res, 2005, 37: 468–473.
71. Krämer E, Seeger H, Krämer B, Wallwiener D, Mueck AO. Characterization of the stimulatory effect of medroxyprogesterone acetate and chlormadinone acetate on growth factor treated normal human breast epithelial cells. J Steroid Biochem Mol Biol, 2006, 98: 174–178.
72. Seeger H, Wallwiener D, Mueck AO. Effects of estradiol and progestogens on TNF-alpha induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinology, 2008, 24: 576–579.
73. Chetrite GS, Thole HH, Philippe JC, Pasqualini JR. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17betahydroxysteroid dehydrogenase activity. Anticancer Res, 2004, 24: 1433–1438.
74. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat, 2008, 107: 103–111.
75. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol–progestogen therapy. Obstet Gynecol, 2009, 113: 65–73.
76. Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacetric, 2009, 1–11 ([Epub ahead of print]).
77. Franke HR, Vermes I. Differential effects of progestogens on breast cancer celllines. Maturitas, 2003, 46(Suppl. 1): 55–8.
78. Bergeron C, Nogales FF, Rechberger T et al. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17betaoestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas, 2010, 66(2): 201-205.
Рецензия
Для цитирования:
Сметник А.А. МЕНОПАУЗАЛЬНАЯ ГОРМОНОТЕРАПИЯ С ДИДРОГЕСТЕРОНОМ: АСПЕКТЫ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ УЛЬТРАНИЗКИХ ДОЗ. Медицинский Совет. 2017;(2):92-99. https://doi.org/10.21518/2079-701X-2017-2-92-99
For citation:
Smetnik A.A. MENOPAUSAL HORMONE THERAPY WITH DYDROGESTERONE: ASPECTS OF EFFICACY AND SAFETY OF ULTRA-LOW DOSES. Meditsinskiy sovet = Medical Council. 2017;(2):92-99. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-92-99
Просмотров: 596
Послать статью по эл. почте 